VIB9600 + Placebos
Phase 1Terminated 1 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Safety Issues
Conditions
Safety Issues
Trial Timeline
Aug 14, 2018 → Apr 8, 2019
NCT ID
NCT03621605About VIB9600 + Placebos
VIB9600 + Placebos is a phase 1 stage product being developed by Amgen for Safety Issues. The current trial status is terminated. This product is registered under clinical trial identifier NCT03621605. Target conditions include Safety Issues.
What happened to similar drugs?
3 of 4 similar drugs in Safety Issues were approved
Approved (3) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03621605 | Phase 1 | Terminated |
Competing Products
20 competing products in Safety Issues